A Randomized Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Ariad Pharmaceuticals
Start Date
December 17, 2015
End Date
August 29, 2018
Administered By
Duke Cancer Institute
Awarded By
Ariad Pharmaceuticals
Start Date
December 17, 2015
End Date
August 29, 2018